Preserved Ejection, Lost Rhythm: A Narrative Review of the Pathophysiology and Management of Heart Failure with Preserved Ejection Fraction and Concomitant Atrial Fibrillation.

However, in the PARAGON-HF trial, sacubitril/valsartan did not significantly improve AF incidence, HF hospitalizations, and cardiovascular death, although a small trend toward benefit emerged among women and patients with lower EF ranges [ 103 ]. 8.2.5.

also in 722 other papers